Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$13,096 Mln
P/E Ratio
18.36
P/B Ratio
2.73
Industry P/E
87.38
Debt to Equity
0.52
ROE
0.16 %
ROCE
10.11 %
Div. Yield
0 %
Book Value
--
EPS
3.16
CFO
$9,876.30 Mln
EBITDA
$12,722.00 Mln
Net Profit
$5,828.40 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Hologic (HOLX)
| -18.87 | -4.62 | -18.51 | -23.03 | -6.43 | 3.74 | 5.88 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Midcap 400
| -8.56 | -2.23 | -12.15 | -1.56 | 3.51 | 11.83 | 6.44 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Hologic (HOLX)
| 0.89 | -4.49 | -2.29 | 5.12 | 39.49 | 27.03 | -3.84 |
|
S&P Midcap 400
| 12.12 | 14.45 | -14.48 | 23.21 | 11.81 | 24.05 | -12.43 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 206.70 | 58,885.65 | 34.47 | 6.76 | |
| 75.94 | 44,540.81 | 31.95 | 50.15 | |
| 435.09 | 35,736.57 | 41 | 57.66 | |
| 229.30 | 37,047.61 | 52.67 | 13.63 |
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments:... Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. Read more
Chairman, CEO & President
Mr. Stephen P. MacMillan
Chairman, CEO & President
Mr. Stephen P. MacMillan
Headquarters
Marlborough, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Hologic Inc (HOLX) stood at $ 9,731 Mln as on 31-Dec-24
The share price of Hologic Inc (HOLX) is $58.49 (NASDAQ) as of 29-Apr-2025 12:41 EDT. Hologic Inc (HOLX) has given a return of -6.43% in the last 3 years.
Hologic Inc (HOLX) has a market capitalisation of $ 13,096 Mln as on 25-Apr-2025. As per Value Research classification, it is a Mid Cap company.
The P/B ratio of Hologic Inc (HOLX) is 2.73 times as on 25-Apr-2025, a 24% discount to its peers’ median range of 3.59 times.
The P/E ratio of Hologic Inc (HOLX) is 18.36 times as on 25-Apr-2025, a 79% discount to its peers’ median range of 87.38 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Hologic Inc (HOLX) and enter the required number of quantities and click on buy to purchase the shares of Hologic Inc (HOLX).
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment worldwide. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, and specimen radiology solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. The company was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
The CEO & director of Mr. Stephen P. MacMillan. is Hologic Inc (HOLX), and CFO & Sr. VP is Mr. Stephen P. MacMillan.
There is no promoter pledging in Hologic Inc (HOLX).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
5,809
|
|
|
4,135
|
|
|
3,588
|
|
|
3,457
|
| Hologic Inc. (HOLX) | Ratios |
|---|---|
|
Return on equity(%)
|
15.3
|
|
Operating margin(%)
|
25.95
|
|
Net Margin(%)
|
18.42
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Hologic Inc (HOLX) was $0 Mln.
$0.41
(
